CN102770458A - 用于增加Fc融合蛋白的血清半寿期的组合物和方法 - Google Patents

用于增加Fc融合蛋白的血清半寿期的组合物和方法 Download PDF

Info

Publication number
CN102770458A
CN102770458A CN2010800629282A CN201080062928A CN102770458A CN 102770458 A CN102770458 A CN 102770458A CN 2010800629282 A CN2010800629282 A CN 2010800629282A CN 201080062928 A CN201080062928 A CN 201080062928A CN 102770458 A CN102770458 A CN 102770458A
Authority
CN
China
Prior art keywords
fusion protein
modified
amino acid
domain
heterologous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800629282A
Other languages
English (en)
Chinese (zh)
Inventor
J.西拉
J.克诺普夫
R.库马
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of CN102770458A publication Critical patent/CN102770458A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
CN2010800629282A 2009-12-02 2010-12-02 用于增加Fc融合蛋白的血清半寿期的组合物和方法 Pending CN102770458A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26609509P 2009-12-02 2009-12-02
US61/266095 2009-12-02
US32758210P 2010-04-23 2010-04-23
US61/327582 2010-04-23
PCT/US2010/058765 WO2011068993A1 (en) 2009-12-02 2010-12-02 Compositions and methods for increasing serum half-life of fc fusion proteins.

Publications (1)

Publication Number Publication Date
CN102770458A true CN102770458A (zh) 2012-11-07

Family

ID=44115295

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800629282A Pending CN102770458A (zh) 2009-12-02 2010-12-02 用于增加Fc融合蛋白的血清半寿期的组合物和方法

Country Status (11)

Country Link
US (2) US8722615B2 (enExample)
EP (1) EP2507267B1 (enExample)
JP (1) JP2013512674A (enExample)
KR (1) KR20140015152A (enExample)
CN (1) CN102770458A (enExample)
AU (1) AU2010325943A1 (enExample)
BR (1) BR112012013330A2 (enExample)
CA (1) CA2782320A1 (enExample)
IN (1) IN2012DN05169A (enExample)
RU (1) RU2012127383A (enExample)
WO (1) WO2011068993A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105273087A (zh) * 2014-07-14 2016-01-27 复旦大学 NGF-Fc融合蛋白及其制备方法
CN107636154A (zh) * 2015-03-26 2018-01-26 阿塞勒隆制药公司 促滤泡素抑制素相关的融合蛋白及其用途
CN109897115A (zh) * 2012-07-18 2019-06-18 阿珀吉尼科斯股份公司 包含CD95-Fc同种型的混合物的组合物

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
EP2507267B1 (en) 2009-12-02 2016-09-14 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life of fc fusion proteins
US8883982B2 (en) 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
WO2014130659A1 (en) 2013-02-22 2014-08-28 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
EP2969009B1 (en) * 2013-03-15 2018-11-28 Pyranose Biotherapeutics, Inc. Modified fc fusion proteins
GB201316592D0 (en) * 2013-09-18 2013-10-30 Levicept Ltd Fusion protein
SI3063275T1 (sl) 2013-10-31 2020-02-28 Resolve Therapeutics, Llc Terapevtske fuzije nukleaza-albumin in postopki
CA2938066C (en) * 2014-02-02 2025-05-06 Medimmune Limited CHIMERIC PROTEIN COMPOSED OF NERVE GROWTH FACTOR ANTAGONIST DOMAIN AND TUMOR NECROSIS FACTOR-ANTAGONIST DOMAIN-A
CN106456714A (zh) * 2014-03-28 2017-02-22 纽约大学 Fgf23融合蛋白
WO2016069889A1 (en) 2014-10-31 2016-05-06 Resolve Therapeutics, Llc Therapeutic nuclease-transferrin fusions and methods
JP2018517708A (ja) 2015-06-05 2018-07-05 ニューヨーク・ユニバーシティ 抗ブドウ球菌生物学的薬剤のための組成物及び方法
WO2017023855A1 (en) * 2015-07-31 2017-02-09 The General Hospital Corporation Protein prostheses for mitochondrial diseases or conditions
CA3004830A1 (en) * 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies
MA45554A (fr) 2016-07-01 2019-05-08 Resolve Therapeutics Llc Fusions de binucléase optimisées.
CN111315767B (zh) 2017-08-22 2025-03-18 萨纳生物有限责任公司 可溶性干扰素受体及其用途
EP3848388B1 (en) * 2018-09-05 2025-08-20 LG Chem, Ltd. Fusion polypeptide comprising polypeptide region that can be o-glycosylated
CA3124352A1 (en) 2019-01-04 2020-07-09 Resolve Therapeutics, Llc Treatment of sjogren's disease with nuclease fusion proteins
US20230355722A1 (en) 2020-06-29 2023-11-09 Resolve Therapeutics, Llc Treatment of sjogren’s syndrome with nuclease fusion proteins
KR102934708B1 (ko) 2021-09-10 2026-03-05 삼성디스플레이 주식회사 유기금속 화합물 및 이를 포함한 발광 소자
WO2025147696A1 (en) 2024-01-05 2025-07-10 Resolve Therapeutics, Llc Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1524092A (zh) * 2001-07-26 2004-08-25 ÷�¿�˹����ʽ���� 多联免疫粘附
WO2006085938A2 (en) * 2004-06-17 2006-08-17 Wyeth Il-13 binding agents

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US6541610B1 (en) 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US5945397A (en) 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
EP0611302B1 (en) 1991-10-15 2000-03-29 MULLARKEY, Michael F. Receptors for treating late phase inflammatory responses
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
NZ256293A (en) 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
WO1995026985A1 (en) 1994-04-05 1995-10-12 Board Of Regents, The University Of Texas System Modified receptors that continuously signal
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
US7094564B1 (en) 1995-03-15 2006-08-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
AU2363695A (en) 1995-04-27 1996-11-18 Human Genome Sciences, Inc. Human tumor necrosis factor receptors
US7070783B1 (en) 1995-05-09 2006-07-04 The Mathilda And Terence Kennedy Institute Of Rheumatology Small molecular weight TNF receptor multimeric molecule
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5817789A (en) 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US5570401A (en) * 1995-09-22 1996-10-29 General Electric Company BWR containment configuration having partitioned wetwell airspace
ATE247974T1 (de) 1996-12-06 2003-09-15 Amgen Inc Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
US6548644B1 (en) 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US6265535B1 (en) 1997-05-30 2001-07-24 The Trustees Of The University Of Pennsylvania Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
WO1999011662A1 (en) 1997-09-05 1999-03-11 Millennium Biotherapeutics, Inc. Novel molecules of the tnfr-ligand-related protein family and uses thereof
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
CA2310575A1 (en) 1997-11-07 1999-05-20 Uab Research Foundation Method for the augmentation of gene expression
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
CA2321105A1 (en) 1998-02-17 1999-08-19 Incyte Pharmaceuticals, Inc. Human short-chain tnf-receptor family protein
BR9908226A (pt) 1998-02-25 2000-10-24 Lexigen Pharm Corp Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo
DE69940808D1 (de) 1998-03-04 2009-06-10 Bristol Myers Squibb Co Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
WO1999053059A1 (en) * 1998-04-16 1999-10-21 Genentech, Inc. Secretion of glycosylated proteins using a tissue plasminogen activator pro-sequence
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
SE9803710L (sv) 1998-09-25 2000-03-26 A & Science Invest Ab Användning av vissa substanser för behandling av nervrotsskador
EP1123314B1 (en) 1998-10-20 2004-02-18 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Use of a cytokine-producing lactococcus strain to treat colitis
AU764479B2 (en) 1998-10-29 2003-08-21 Bristol-Myers Squibb Company Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6673908B1 (en) 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
AU2000236029A1 (en) 1999-02-23 2000-09-14 Anne Chew Receptor isogenes: polymorphisms in the tissue necrosis factor receptor
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20030148955A1 (en) 1999-04-19 2003-08-07 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
EP1206265B1 (en) 1999-06-30 2003-11-12 Merck & Co., Inc. Src kinase inhibitor compounds
AU6836200A (en) 1999-08-10 2001-03-05 Glaxo Group Limited Use of ep4 receptor ligands in the treatment of, inter alia, neuropathic pain and colon cancer
NZ529329A (en) 1999-08-25 2005-06-24 Immunex Corp Compositions and methods for improved cell culture
GB9927681D0 (en) 1999-11-23 2000-01-19 Glaxo Group Ltd Protein
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
EP1254227A2 (en) 2000-02-11 2002-11-06 Amgen Inc. Fusion receptor from tnf family
WO2001064889A2 (en) 2000-03-02 2001-09-07 Xencor Tnf-alpha variants for the treatment of tnf-alpha related disorders
AU4935701A (en) 2000-03-24 2001-10-08 Genentech Inc Use of insulin for the treatment of cartilagenous disorders
US6800300B1 (en) 2000-03-31 2004-10-05 Vasogen Ireland Limited Method for treating autoimmune and alloimmune diseases
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
ES2327102T3 (es) 2000-09-05 2009-10-26 Amgen Inc. Moleculas analogas al receptor de tnf y usos de las mismas.
US6610750B1 (en) 2000-09-15 2003-08-26 Laboratoires Negma Treatment of osteoarthritis
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
US20020150582A1 (en) 2001-02-08 2002-10-17 Friedrichs Gregory S. Method of treating or inhibiting cellular injury or cell death
EE200300408A (et) 2001-02-23 2003-12-15 Immunex Corporation Aktiivsete valkude saagise suurendamine
US6972327B1 (en) 2001-05-08 2005-12-06 Immunex Corporation Regeneration of chromatography material
EP2292273A3 (en) 2001-10-10 2011-11-23 BioGeneriX AG Remodeling and glycoconjugation of peptides
MXPA04004166A (es) 2001-11-07 2004-07-08 Hoffmann La Roche Aminopirimidinas y piridinas.
JP4363986B2 (ja) 2001-12-21 2009-11-11 イミュネックス・コーポレーション タンパク質の精製方法
US20040258678A1 (en) 2002-02-22 2004-12-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2476934C (en) 2002-02-27 2009-06-16 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
ES2557741T3 (es) 2002-03-27 2016-01-28 Immunex Corporation Procedimientos para incrementar la producción de polipéptidos
US6924124B1 (en) 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
US7067279B1 (en) 2002-08-23 2006-06-27 Immunex Corporation Cell culture performance with betaine
US6974681B1 (en) 2002-08-23 2005-12-13 Immunex Corporation Cell culture performance with vanadate
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
WO2004091499A2 (en) 2003-04-09 2004-10-28 Neose Technologies, Inc. Intracellular formation of peptide conjugates
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
EP1636264A2 (en) 2003-06-24 2006-03-22 MERCK PATENT GmbH Tumour necrosis factor receptor molecules with reduced immunogenicity
SG145712A1 (en) 2003-08-01 2008-09-29 Amgen Inc Crystalline tumor necrosis factor receptor 2 polypeptides
WO2005014035A2 (en) 2003-08-08 2005-02-17 Novo Nordisk Health Care Ag Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
US7268116B2 (en) 2003-10-02 2007-09-11 Genhunter Corp. Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins
KR20050082389A (ko) 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
US7507745B2 (en) 2004-02-20 2009-03-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on fluorenecarboxylic acid esters and soluble TNF receptor fusion proteins
AU2005257064B2 (en) 2004-06-28 2012-05-10 Yeda Research And Development Co. Ltd. Chimeric proteins and uses thereof
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
EP1844069A4 (en) 2005-01-28 2009-05-20 Apollo Life Sciences Ltd MOLECULES AND CHIMESE MOLECULES THEREOF
EP2305246B1 (en) 2005-01-31 2015-08-26 The Trustees of the University of Pennsylvania Tumor necrosis factor inhibitors
US8124732B2 (en) 2005-06-24 2012-02-28 Synageva Biopharma Corp. Composition comprising isolated human CTLA4-Fc fusion protein produced in a transgenic chicken
EP2377554A1 (en) 2005-07-22 2011-10-19 Amgen, Inc Concentrated protein lyophilates, methods and uses
CN1954882A (zh) 2005-10-14 2007-05-02 李海 长效人重组可溶性肿瘤坏死因子α受体在制备防治肝衰竭药物中的用途
US7626895B2 (en) 2005-12-01 2009-12-01 International Business Machines Corporation Removable media battery pack for powering a media accessor of an automated data-storage library
EP2089521A1 (en) 2006-02-08 2009-08-19 Ercole Biotech, Inc. Soluble tnf receptors and their use in treatment of disease
US7504106B2 (en) 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
US20100056428A1 (en) 2006-09-01 2010-03-04 Novo Nordisk Health Care Ag Modified proteins
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
IL182956A0 (en) 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
EP2152751A1 (en) 2007-05-31 2010-02-17 Genmab A/S Fusion or linked proteins with extended half life
EP2162535A4 (en) 2007-06-04 2011-02-23 Novo Nordisk As O-linked glycosylation using N-acetylglucosamine transferases
US8067548B2 (en) 2007-07-26 2011-11-29 Novagen Holding Corporation Fusion proteins having mutated immunoglobulin hinge region
ES2536772T3 (es) 2007-09-21 2015-05-28 The Regents Of The University Of California El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
CN102037004A (zh) 2008-01-08 2011-04-27 生物种属学股份公司 使用寡糖基转移酶的多肽的糖缀合
DK3750552T5 (da) 2008-08-14 2024-08-26 Acceleron Pharma Inc Gdf-fælder
MX355042B (es) * 2009-06-08 2018-04-02 Acceleon Pharma Inc Metodos para aumentar adipositos termogenicos.
CN107267520A (zh) * 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
EP2507267B1 (en) 2009-12-02 2016-09-14 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life of fc fusion proteins
US8883982B2 (en) * 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1524092A (zh) * 2001-07-26 2004-08-25 ÷�¿�˹����ʽ���� 多联免疫粘附
WO2006085938A2 (en) * 2004-06-17 2006-08-17 Wyeth Il-13 binding agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RAJU T. S. ET AL.: ""Glycoengineering of Therapeutic Glycoproteins: In Vitro Galactosylation and Sialylation of Glycoproteins with Terminal N-Acetylglucosamine and Galactose Residues.", 《BIOCHEMISTRY》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109897115A (zh) * 2012-07-18 2019-06-18 阿珀吉尼科斯股份公司 包含CD95-Fc同种型的混合物的组合物
CN105273087A (zh) * 2014-07-14 2016-01-27 复旦大学 NGF-Fc融合蛋白及其制备方法
CN107636154A (zh) * 2015-03-26 2018-01-26 阿塞勒隆制药公司 促滤泡素抑制素相关的融合蛋白及其用途
US11001614B2 (en) 2015-03-26 2021-05-11 Acceleron Pharma Inc. Method for treating a muscle-related disorder with follistatin-related fusion proteins

Also Published As

Publication number Publication date
EP2507267B1 (en) 2016-09-14
EP2507267A1 (en) 2012-10-10
IN2012DN05169A (enExample) 2015-10-23
RU2012127383A (ru) 2014-01-10
JP2013512674A (ja) 2013-04-18
US8722615B2 (en) 2014-05-13
US20150010555A1 (en) 2015-01-08
BR112012013330A2 (pt) 2017-03-28
EP2507267A4 (en) 2013-05-29
KR20140015152A (ko) 2014-02-06
US20110171218A1 (en) 2011-07-14
AU2010325943A1 (en) 2012-06-21
CA2782320A1 (en) 2011-06-09
WO2011068993A1 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
US8722615B2 (en) Compositions and methods for increasing serum half-life
US8883982B2 (en) Compositions and methods for increasing serum half-life
JP7827324B2 (ja) インターロイキン－２バリアントおよびその使用方法
CN103168048B (zh) 二聚vstm3融合蛋白和相关的组合物和方法
CN110028587B (zh) 用于调节血糖和脂质的增效型双功能蛋白
CN119258195A (zh) April和baff抑制性免疫调节蛋白及其使用方法
ES2239242T3 (es) Inmunoadhesion concatemerica.
EP2214690B1 (en) Melanocortin receptor binding mimetibodies, compositions, methods and uses
US9731007B2 (en) Tumour necrosis factor receptor fusion proteins and methods of using the same
WO2018166468A1 (zh) IgG样长效免疫融合蛋白及其应用
WO2022117044A1 (en) Glp-1/gcg dual receptor agonist polypeptide and fusion protein thereof
KR20190084885A (ko) IgE Fc 수용체의 알파 서브유닛의 세포외 도메인, 이를 포함하는 약학적 조성물 및 이의 제조방법
EP1812046B1 (en) Melanocortin receptor binding mimetibodies, compositions, methods and uses
US20050250185A1 (en) OGH fusion polypeptides and therapeutic uses thereof
CN109824780A (zh) 一种用于研发药物的双功能融合蛋白平台
HK1106445B (en) Melanocortin receptor binding mimetibodies, compositions, methods and uses
CA2704446A1 (en) Melanocortin receptor binding mimetibodies, compositions, methods and uses

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121107